Clinical Trial

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

Study acronym: BRAVE-HCM
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 21, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07103655
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Hypertrophic Cardiomyopathy (HCM)
Enrollment 132 participants
Start Date 2026-01-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-21